Aurobindo Pharma gains 3% on red flags from USFDA

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Aurobindo Pharma share price rose more than 3 percent in the early trade on February 26 after the company received EIR from USFDA.

The company has received the establishment inspection report (EIR) with voluntary action initiated (VAI) status from United States Food and Drug Administration (USFDA).

USFDA inspected Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad of the company.

At 09:25 hrs, Aurobindo Pharma was quoting at Rs 511.50, up Rs 7.40, or 1.47 percent on the BSE.

The share touched its 52-week high Rs 838.00 and 52-week low Rs 389.70 on 30 April, 2019 and 14 November, 2019, respectively.

Currently, it is trading 39.14 percent below its 52-week high and 30.87 percent above its 52-week low.